Equibles does not estimate personal net worth.
Get an email with a short summary when SAB Biotherapeutics, Inc. publishes a filing, an earnings call transcript or a press release.
Get SABS alertsAlexandra Kropotova has spoken on 2 earnings calls across 1 company, most recently for SAB Biotherapeutics, Inc. on November 5, 2026. SAB Biotherapeutics, Inc. is classified in the Biotechnology industry within the Healthcare sector. Other leadership on record at SAB Biotherapeutics, Inc. includes Samuel J. Reich (CEO and Board Member), David Zaccardelli (Chairman and Board Member), Lucy To (CFO) and 7 others.
“We are very hopeful about our upcoming data release next year.”
“As far as the baseline characteristics in the ongoing safeguard trial, as you know, protocol requires, our safeguard protocol requires at least 36 patients 5 to 11 years of age, two-thirds of the population below 18 years of age, and as far as the adult population, we are capping the adult population at 45 patients…”
Proxy statement
Start not stated–present
Last confirmed April 30, 2026
Biotechnology · Healthcare
